APL, Information and SupportInspired by Anita’s Journey through Acute Promyelocytic Leukemia

–_004_D7CE2E25B2A8664C8B704ECE815F926F1FC9C340F3fallbrookbsnl_
Content-Type: multipart/alternative;
boundary=”_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C340F3fallbrookbsnl_”

–_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C340F3fallbrookbsnl_
Content-Type: text/plain; charset=”us-ascii”
Content-Transfer-Encoding: quoted-printable

Here is an interesting article on improved APL survival stats in developing=
countries,

http://www.hemonctoday.com/article.aspx?rid=3D51173

Its good to see treatments such as Arsenic and Retinoic Acid having a world=
wide impact on APL.

Chris

[cid:bayside.jpg]
Bayside Networks
Information Technology Service and Support

http://baysidenetworks.com

3655 Nobel Drive Suite 640
San Diego CA 92122-1052

858-654-4080 Phone
877-654-4080 Toll-free

–_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C340F3fallbrookbsnl_
Content-Type: text/html; charset=”us-ascii”
Content-Transfer-Encoding: quoted-printable

Bayside Networks Information Technology Ser= vice and Support http://baysidenetworks.com

3655 Nobel Drive = Suite 640 San Diego CA 92122-1052 858-654-4080 Phone 877-654-4= 080 Toll-free

–_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C340F3fallbrookbsnl_–

–_004_D7CE2E25B2A8664C8B704ECE815F926F1FC9C340F3fallbrookbsnl_
Content-Type: application/octet-stream; name=”bayside.jpg”
Content-Description: bayside.jpg
Content-Disposition: inline; filename=”bayside.jpg”; size=3514;
creation-date=”Mon, 07 Dec 2009 13:45:55 GMT”;
modification-date=”Mon, 07 Dec 2009 13:45:55 GMT”
Content-ID:
Content-Transfer-Encoding: base64
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×8M9Fm0P
wnbwXabLy4Zrm4XPKs3RT7qoRTjjKk96/Oc6xkcXi5Sg/dWi9F1+bu/mfUYKh7CioPc3NWFm2l3a
6js+xGBxcbzhfL2ndn2xmvPw7qKrH2XxXVvXp+J0ztyvm2Plc674jsgtta3d9BGqq3lxXTRqGYBm
woPHzEn61+w/UsJV96cU35q+2i19D5aliHGNk397Os1fSLHRvEGp6Mt5ILexjIgcQhmeTYjKjDIA
+8cn26c142HxdXFYenXcdZPXXpdptaPtsTiMPQp4iUKkml+pf8CeFR4qv54Z7l7eztgjXBibbK+4
nCqf4c7TluoHTk5HNmmZ/wBn01KKvKV7X206vvvovv00dZZgViJOUtkXvi18LtBbTdOi0jwba3Nu
jyG6kit/NuixwULScysOXz8×5IyO458g4lxSqVHXxDT0sm7R87L4U9unp5+lmGDappUIr9TlPCfi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–_004_D7CE2E25B2A8664C8B704ECE815F926F1FC9C340F3fallbrookbsnl_–

–_004_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33CBFfallbrookbsnl_
Content-Type: multipart/alternative;
boundary=”_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33CBFfallbrookbsnl_”

–_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33CBFfallbrookbsnl_
Content-Type: text/plain; charset=”us-ascii”
Content-Transfer-Encoding: quoted-printable

I wish Dana Bible the best for his treatment.

According to this article he is going in for 30 days of initial treatment f=
or APL:

http://www.sportingnews.com/college-football/article/2009-11-24/north-carol=

ina-nc-state-preview

[cid:bayside.jpg]
Bayside Networks
Information Technology Service and Support

http://baysidenetworks.com

3655 Nobel Drive Suite 640
San Diego CA 92122-1052

858-654-4080 Phone
877-654-4080 Toll-free

–_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33CBFfallbrookbsnl_
Content-Type: text/html; charset=”us-ascii”
Content-Transfer-Encoding: quoted-printable

Bayside Networks Information Technology Ser= vice and Support http://baysidenetworks.com

3655 Nobel Drive = Suite 640 San Diego CA 92122-1052 858-654-4080 Phone 877-654-4= 080 Toll-free

–_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33CBFfallbrookbsnl_–

–_004_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33CBFfallbrookbsnl_
Content-Type: application/octet-stream; name=”bayside.jpg”
Content-Description: bayside.jpg
Content-Disposition: inline; filename=”bayside.jpg”; size=3514;
creation-date=”Wed, 25 Nov 2009 08:49:46 GMT”;
modification-date=”Wed, 25 Nov 2009 08:49:46 GMT”
Content-ID:
Content-Transfer-Encoding: base64
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×8M9Fm0P
wnbwXabLy4Zrm4XPKs3RT7qoRTjjKk96/Oc6xkcXi5Sg/dWi9F1+bu/mfUYKh7CioPc3NWFm2l3a
6js+xGBxcbzhfL2ndn2xmvPw7qKrH2XxXVvXp+J0ztyvm2Plc674jsgtta3d9BGqq3lxXTRqGYBm
woPHzEn61+w/UsJV96cU35q+2i19D5aliHGNk397Os1fSLHRvEGp6Mt5ILexjIgcQhmeTYjKjDIA
+8cn26c142HxdXFYenXcdZPXXpdptaPtsTiMPQp4iUKkml+pf8CeFR4qv54Z7l7eztgjXBibbK+4
nCqf4c7TluoHTk5HNmmZ/wBn01KKvKV7X206vvvovv00dZZgViJOUtkXvi18LtBbTdOi0jwba3Nu
jyG6kit/NuixwULScysOXz8×5IyO458g4lxSqVHXxDT0sm7R87L4U9unp5+lmGDappUIr9TlPCfi
HRvCviOCS/XU7250qMqlnawm4uXkKtFiQk7Y2ALEiVkY/KQCDmvZx+AxGYYZqnyxVR/E3yxtdS06
yT0tyqS31TR5+D5cLUdSs9ex0V38YZLXXn1C1+FF48RXbJffa7VbspkcbFLbunTf2FeXT4SVSgqU
8cr9I8s+W/q7W9eU7nnFLn0j8/6/zPSvhv468P8Aj7RH1TQZph5Mhiuba4TZPbyf3XXJx9QSOvPB
x8pnOSYrJ66o4lLVXTWqa7p/0z1KGIhXjeBn/FnxHDp2jyaLCVkvL+JkdevlwnhmP1GVH4n+E11Z
Bl8q1ZYiWkYP730+7d/d1OXMcYqFOy3Zxfh34WxeI9Hg1mTXbi2a4Lfukt1YLtYr1Jz/AA5r3sZx
NLBVnQVJO1tbvqr/AKnFg8uhVoxnfc6H4x+H9yxa7Y2DySglb14VZmK4G1yo6gYILYyBjPA48zh3
H2vh6k7L7N7fNX8+36m2bYR1Ic8Fr+hyHhnxTd+HLG5TTLG0N5cyqZLi4Z3Uxqp2rsBXkMxOc9D9
Me3jcsp46cXWk+VLRKy1b1d9ei2seVhMx+q0nGMbsk1/xh4q1O3S31CVrGGWIP5dvbPbrMhzhssS
xU8jhtp9KjCZTgaEnKkuZp7tqVn20sr+qujXFZliWkmuW/4nMxtCs0dtnyl4GfLbai5Az8oPAz0A
J9BXrSUmnLf5r9X18zy4R55K7tfqOu0T/SIPOVkUsnmxghWGPvLuAOPqKVNv3ZW17fpo3+ZU4KnU
snc7KbxxrenwNZWehabod0I1SZxZsjnA4KxtjbgHgNvH8q8OOS4atL2k6sqkdbe8mvvV7+duU9ir
mtSl7vs+VmPpejatq3nAaLfXN7qDRPBqVyZ0iXnLOxCFWDLgAnOOMdq7a+MoYe37xKML3iuVvyS1
TVn0+8wpUKuIv7SDvLaT2R7f4a0tNF0Gz0uN/M8iPDPz87k5ZsEnGWJOO2cV+f43EvFV5VmrXf4d
PwPpKFJUaaguhfljSWJopUV43UqysMhgeoI7iueMnFpp2aNXqef+J/hrYSafEvhuCO1ulkG83F3M
ytHg5HO/nO09O3WvpMDxFVjUf1t3jboo3v8AgeTisqpzhakkn8zzO3ju9T0yTWJphc6dpYtop1ku
2WURNJtCJ8rAY5zyMZ719ZOVOhVVCKtOfM17qtdK93qv1PJhCdVOpV1UOnl5FZTDLexwxSRW8dxc
CODz5vlRWfC7nxyACMnHvWr5owcpK7Su7LstbLz6I5PZqrW5YKyb+47DX/AskHgQaraz6fNcW1vc
zX00V1I8cqLkqI+NpIUY6Lz3714mFztSx/sZqSUnFRTSTTe99b6vXroexUytRoRcbXWrfc1p9NtP
iJpE+uaRZxWeqJdCGR5rpzG6qi/3QR0Zf4e1cUcRUyWtHD15c0LXVkrq7ffXo+vU2qUYZjSdSEbS
21Ou+H+kavo+iLb6vfi4kAVYoU5S3RRgKGPLHHU8DsOmT4ubYuhia/NQjZa3fVt9bdP69F6GFo1K
UOWcr/odHXlHSFABQAUAeG27t/aHxFbPMXn7PbM5J/kK/Q5JezwK78v/AKSeGoJSxB6H8HGL/DnS
2Y5JMxJ/7bSV8vxErZjUS8v/AElHo4FJYeKR19eIdYUAFAH/2Q==

–_004_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33CBFfallbrookbsnl_–

–_004_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33682fallbrookbsnl_
Content-Type: multipart/alternative;
boundary=”_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33682fallbrookbsnl_”

–_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33682fallbrookbsnl_
Content-Type: text/plain; charset=”us-ascii”
Content-Transfer-Encoding: quoted-printable

APL isn’t mentioned in the news very often – it’s a rare disease so that’s =
understandable. Here’s an article that briefly mentions a girl named Ashe=
ly Jones that was diagnosed and treated at 9 year’s old and is doing fine n=
ow at 14,

http://www.explorernews.com/articles/2009/11/11/news/doc4af9f3fbe35e8187370=

243.txt

[cid:bayside.jpg]
Bayside Networks
Information Technology Service and Support

http://baysidenetworks.com

3655 Nobel Drive Suite 640
San Diego CA 92122-1052

858-654-4080 Phone
877-654-4080 Toll-free

–_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33682fallbrookbsnl_
Content-Type: text/html; charset=”us-ascii”
Content-Transfer-Encoding: quoted-printable

Bayside Networks Information Technology Ser= vice and Support http://baysidenetworks.com

3655 Nobel Drive = Suite 640 San Diego CA 92122-1052 858-654-4080 Phone 877-654-4= 080 Toll-free

–_000_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33682fallbrookbsnl_–

–_004_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33682fallbrookbsnl_
Content-Type: application/octet-stream; name=”bayside.jpg”
Content-Description: bayside.jpg
Content-Disposition: inline; filename=”bayside.jpg”; size=3514;
creation-date=”Wed, 11 Nov 2009 09:09:09 GMT”;
modification-date=”Wed, 11 Nov 2009 09:09:09 GMT”
Content-ID:
Content-Transfer-Encoding: base64

/9j/4AAQSkZJRgABAQEASABIAAD/4QAWRXhpZgAATU0AKgAAAAgAAAAAAAD/2wBDAAUDBAQEAwUE
BAQFBQUGBwwIBwcHBw8LCwkMEQ8SEhEPERETFhwXExQaFRERGCEYGh0dHx8fExciJCIeJBweHx7/
2wBDAQUFBQcGBw4ICA4eFBEUHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4e
Hh4eHh4eHh4eHh7/wAARCAA7ADsDAREAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQF
BgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS
0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4
eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi
4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREA
AgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl
8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImK
kpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP0
9fb3+Pn6/9oADAMBAAIRAxEAPwD7KqQOL1z4leHtNumt4EvNUZG2u1kqMin03Oyhsd9pOMEdeK97
DcO4uvHmk1D/ABXv9yTa+dvuOCtmeHoy5W7vyON8V/ELVdUlaDSWl0yxxjII8+TjnLDOwegU54zu
5wPdwGQ0MOuatacv/JV8uvz08up5WLziUtKOi7nEyQRSOZJY1lkJ3M8nzMxPUknkn3PNfQKcoqyd
keO6s27tne+APHculyfYNfuri408r+6uHDSyQtnoxGWdTnryVIHY/L83m2SRxC9phopT6rRJ+myT
XyT9d/by/NLe5XfzPS9D8QaLrYP9l6lBcuoy0YbEiD1ZDhl7dR3r5TFYDE4X+NBrz6fJ7M9ynWp1
VeDualcZqFAHmHxo8VSwbfDGluxuJUEl6yNjbGcgIWH3d2MnvjHBDEj67hvK4z/2utstI+ve3W3T
pfrda+RmmLVOPs4vV7+h5WLa4OCb6VMDG2KNAn4Agn9a+w9pD+X773/NfkfMuS7C771G8vyY5uOJ
N+0f8CGCQfpnOD04FFqb1vby3/r8PmO0HqKqX24lri2IwMAQMD7876TdLon9/wDwBe5c1tC8L+Kf
E1tM+hTaDBJAwEsd5PMWGc4OFjxg4ODk9MEA9OLFZlgsBJLEKbT2cVG34vddVb5noYXLXiIc0ZIw
NB1HWItYvbLUbK40rWNIuWiM9s7eU7KcFopMDIOOVPY4IOSK9LFYfDyowqUpKdOor2dr69JL8n31
XQ55e0wlX3XZo+j/AANrDa94UsNTlx57oUnwMDzUYo+B6blJHsRX5bmmEWExc6S2Wq9HqvwevmfX
4er7alGfc26882PmzXNSivNT1HWJ5QkdzcvN5kpC/ITiPcfZAi/gBX6rhcPKlShQitYpKy79beru
z4nF1XWrykigL+AxGQLclR6W0hJ4zwNvP4V0+wle2n3r/M5+RhPf2cFulxJOojf7mOS/sAOSfYUQ
oVJycUtUP2cr2sNsdRt9RRjpSXOpyr96Cyt3nmXp95FBZeo5IAGRnrTq4eVF/vmoLvJpL727P5Gk
MNUm7RRd8G+L7rSfEUwtba6sdTt023NhqVs0TtESOqnnBIGGHcdxkHnzHKYYnDrnkpQe0otNX9fz
T/PVdWHrVcDO7XqjftfDeueJJptW0a0hktb65mlEktwqLC5kYvHJ1b5WyMhWyMN3IHnVMxw2BSo1
5NSiktE9VZWa6aro2rO66Xe88vqYqftae0tfQ7DUU8U+BNC0+LRrO11DTbWNptRlK/OZGcs5+8Cq
c8EByoGTwvPh0Xgc3rzdeTjOTtFdLJWXSzfdXV3tq9PWkq2EpxjSjeKWvc7nQNVtdb0e21SyLGGd
cgMMFSCQyn3BBB9xXz2Lws8LWlRqbr+k/mtTvpVI1IKcdmfOE2kX+m6i1jq8KQz2SxoIFYMFYxq2
7I4z82B1wPqa/U44qlXp+0oO6lfX5tW/A+MxMJUZuElZk1ZnKWND1u88OXMo0m/isJL1g8iCKItM
V7/MpJ6joayxWCp42K9tHmUdtZaX9HY7cPja9CLUNvQ9B+HnjS+u7650u8tLaa9uInnt5ooxEbmV
EHyyEHBcqowwAGEI7DPzWb5PSpwjWpyaimk03flTe68k+mru/U9rLswdduEl735nmGsNPrHiO21/
VLu6n1QIbVRyu8Mf9UIu3zDIUDOR3Oa+uw6jhsPLDUYpQ3+7rzenV6WPFxFWtXqNTWp7×8M9Fm0P
wnbwXabLy4Zrm4XPKs3RT7qoRTjjKk96/Oc6xkcXi5Sg/dWi9F1+bu/mfUYKh7CioPc3NWFm2l3a
6js+xGBxcbzhfL2ndn2xmvPw7qKrH2XxXVvXp+J0ztyvm2Plc674jsgtta3d9BGqq3lxXTRqGYBm
woPHzEn61+w/UsJV96cU35q+2i19D5aliHGNk397Os1fSLHRvEGp6Mt5ILexjIgcQhmeTYjKjDIA
+8cn26c142HxdXFYenXcdZPXXpdptaPtsTiMPQp4iUKkml+pf8CeFR4qv54Z7l7eztgjXBibbK+4
nCqf4c7TluoHTk5HNmmZ/wBn01KKvKV7X206vvvovv00dZZgViJOUtkXvi18LtBbTdOi0jwba3Nu
jyG6kit/NuixwULScysOXz8×5IyO458g4lxSqVHXxDT0sm7R87L4U9unp5+lmGDappUIr9TlPCfi
HRvCviOCS/XU7250qMqlnawm4uXkKtFiQk7Y2ALEiVkY/KQCDmvZx+AxGYYZqnyxVR/E3yxtdS06
yT0tyqS31TR5+D5cLUdSs9ex0V38YZLXXn1C1+FF48RXbJffa7VbspkcbFLbunTf2FeXT4SVSgqU
8cr9I8s+W/q7W9eU7nnFLn0j8/6/zPSvhv468P8Aj7RH1TQZph5Mhiuba4TZPbyf3XXJx9QSOvPB
x8pnOSYrJ66o4lLVXTWqa7p/0z1KGIhXjeBn/FnxHDp2jyaLCVkvL+JkdevlwnhmP1GVH4n+E11Z
Bl8q1ZYiWkYP730+7d/d1OXMcYqFOy3Zxfh34WxeI9Hg1mTXbi2a4Lfukt1YLtYr1Jz/AA5r3sZx
NLBVnQVJO1tbvqr/AKnFg8uhVoxnfc6H4x+H9yxa7Y2DySglb14VZmK4G1yo6gYILYyBjPA48zh3
H2vh6k7L7N7fNX8+36m2bYR1Ic8Fr+hyHhnxTd+HLG5TTLG0N5cyqZLi4Z3Uxqp2rsBXkMxOc9D9
Me3jcsp46cXWk+VLRKy1b1d9ei2seVhMx+q0nGMbsk1/xh4q1O3S31CVrGGWIP5dvbPbrMhzhssS
xU8jhtp9KjCZTgaEnKkuZp7tqVn20sr+qujXFZliWkmuW/4nMxtCs0dtnyl4GfLbai5Az8oPAz0A
J9BXrSUmnLf5r9X18zy4R55K7tfqOu0T/SIPOVkUsnmxghWGPvLuAOPqKVNv3ZW17fpo3+ZU4KnU
snc7KbxxrenwNZWehabod0I1SZxZsjnA4KxtjbgHgNvH8q8OOS4atL2k6sqkdbe8mvvV7+duU9ir
mtSl7vs+VmPpejatq3nAaLfXN7qDRPBqVyZ0iXnLOxCFWDLgAnOOMdq7a+MoYe37xKML3iuVvyS1
TVn0+8wpUKuIv7SDvLaT2R7f4a0tNF0Gz0uN/M8iPDPz87k5ZsEnGWJOO2cV+f43EvFV5VmrXf4d
PwPpKFJUaaguhfljSWJopUV43UqysMhgeoI7iueMnFpp2aNXqef+J/hrYSafEvhuCO1ulkG83F3M
ytHg5HO/nO09O3WvpMDxFVjUf1t3jboo3v8AgeTisqpzhakkn8zzO3ju9T0yTWJphc6dpYtop1ku
2WURNJtCJ8rAY5zyMZ719ZOVOhVVCKtOfM17qtdK93qv1PJhCdVOpV1UOnl5FZTDLexwxSRW8dxc
CODz5vlRWfC7nxyACMnHvWr5owcpK7Su7LstbLz6I5PZqrW5YKyb+47DX/AskHgQaraz6fNcW1vc
zX00V1I8cqLkqI+NpIUY6Lz3714mFztSx/sZqSUnFRTSTTe99b6vXroexUytRoRcbXWrfc1p9NtP
iJpE+uaRZxWeqJdCGR5rpzG6qi/3QR0Zf4e1cUcRUyWtHD15c0LXVkrq7ffXo+vU2qUYZjSdSEbS
21Ou+H+kavo+iLb6vfi4kAVYoU5S3RRgKGPLHHU8DsOmT4ubYuhia/NQjZa3fVt9bdP69F6GFo1K
UOWcr/odHXlHSFABQAUAeG27t/aHxFbPMXn7PbM5J/kK/Q5JezwK78v/AKSeGoJSxB6H8HGL/DnS
2Y5JMxJ/7bSV8vxErZjUS8v/AElHo4FJYeKR19eIdYUAFAH/2Q==

–_004_D7CE2E25B2A8664C8B704ECE815F926F1FC9C33682fallbrookbsnl_–

Hello everyone. My 21-month-old nephew (adjusted age 19 months) was diagnosed with APL on Saturday. I know that you will all understand our shock and grief. Here’s my question: he is at the Boston Children’s Hospital. They say they very rarely see such a young child with APL. Are there other people here with experience in this? Since I live in China, where ATRA was discovered, I am trying to contact Dr Wang Zhenyi at the Ruijin Hospital in Shanghai, to ask for a consultation on behalf of my brother’s family, since APL apparently is commoner here in China than in the West, and the hope is that he will have experience with treating such young children. Does anyone know him or have a contact for him? So far I have not been able to get through to the hospital. They have a terrible phone manner and no-one in hematology is even picking up. Thanks everyone. Didi/Beijing.

I’m so happy to have found this site! My name is Patty Chambers and I was diagnosed with APL November 2005, when I was 19 years old. I’m now a 21 year old college student and am currently in the “maintenance” phase of treatment (taking oral chemotherapy such as Atra, Methotrexate, and Mercatopurine). I was apart of a research study where I also got treated with Arsenic 5 times a week for 6 weeks. I am so happy that this website is dedicated to all of the people that have or have had APL, we all have gone through alot and continue to live through it everyday, atleast we have somewhere to share our own experiences.

Patty

Occasionally someone askes me “When will they find a cure for leukemia?”
Of course this is a tremendously naive question that ignores the  tremendous improvements in treatments that have developed in the last  20 years.   I usually answer the question by trying to explain that  cancer has to be fought on hundreds of different fronts and that while  many battles have been won, the war is certainly a long way from being  over.
My answer on this type of question always felt a little bit hollow.   What exactly was a battle in this context?   Why are the survival  statistics for certain types of cancer so much better now than they  were 20 years ago?
Today, I read a short article in the health section of Slate.com  that provided a great explanation on how the treatment of juvenile  leukemia was improved from a 20% to 80% survival rate between the early  70’s and late 90’s.   From my reading across a wide variety of cancer  related subjects, I think this short article provides a good paradigm  for how health treatments are improved for just about every tough  chronic disease.
Here’s the article- http://www.slate.com/id/2193294/  (also pasted below)

Old Drugs, New Tricks Why big health advances rarely involve new medicines.

By Darshak Sanghavi

Posted Tuesday, June 10, 2008, at 1:36 PM ET

Leukaemic cells

Between the early 1970s and the late 1990s, the  long-term survival rate of children with leukemia skyrocketed from less  than 20 percent to around 80 percent. Over this relatively short  period, many children presumed to be dying instead ended up living. As  remarkable as the surge is the reason for it. Dr. Steve Sallan, the  chief of staff at the Dana-Farber Cancer Institute in Boston, recently  told me that not a single newly discovered drug was involved. Nobody  invented some magical genetic therapy either. So what changed?
Too often, medical advances get advertised as the work of  swashbuckling doctors and patients who take big risks against big odds  and seize miraculous results with new treatments taken straight from  the lab. That narrative is misleading. As with pediatric leukemia, the  reality often is far less dramatic but no less impressive, and therein  lie critical lessons for patients with many chronic, tough-to-treat  diseases like asthma, attention-deficit disorder, and obesity.
The leukemia doctors saved lives simply by refining the use of  old-school drugs like doxorubicin and asparaginase. Over the course of  almost a dozen clinical trials, they painstakingly varied the doses of these older drugs, evaluated the benefit of continuing  chemotherapy in some kids who appeared to be in remission, and tested  the benefit of injecting drugs directly into the spinal column. The  doctors gradually learned what drug combinations, doses, and sites of  injection worked best. And they kept at it. With each small innovation,  survival rates crept forward a bit—a few percent here and there every  couple of years—and over decades those persistent baby steps added up  to a giant leap.

Today, we’re far more likely to hear exaggerated tales of  breakthrough new drugs, aggressively marketed and hyped. But it’s the  leukemia story that’s the historical norm. Back in the early 20th century, for example—decades before the discovery of antibiotics—tuberculosis mortality fell almost 70 percent (subscription required) due largely to careful studies of nutrition and hygiene. From 1980 to 2000, death from heart disease plummeted an astonishing 50 percent,  almost entirely from the use of existing medicines and surgical  treatments. These were gradually tweaked, like leukemia therapy, in  response to scores of incremental studies. During the past 30 years,  mortality from diabetes in men also has decreased by half, largely due to improved use of flu vaccines, smoking reduction, and possibly aspirin use—but not a new blockbuster drug.
Of course, new drugs can sometimes change everything. Example: Genentech’s novel angiogenesis inhibitor Lucentis, which restored vision in patients (subscription required) with macular degeneration. But such successes  are incredibly rare and even in cases like Lucentis, often unforeseen.  (James Watson, the co-discoverer of DNA, imprudently predicted in 1998 that angiogenesis inhibitors might “cure cancer in two years”  and said nothing about their use for treating eye disease.) And in  truth, we don’t have that many new drugs to call on anyway. Last year,  for example, the U.S. Food and Drug Administration approved only 19 entirely new drugs, many of which treat pretty rare diseases or offer little benefit over older medications.
If the greatest medical advances depend mostly on small but  consistent improvements in the use of old drugs, why do certain  specialties (such as psychiatry) fall behind others (such as  cardiology) in producing major results, like a 50 percent  population-wide improvement? The difference isn’t related to a lack of  drug choices. A psychiatrist now has a bewildering array of medications  to treat, say, attention-deficit disorder or depression, just as a  cardiologist can choose from dozens of anti-hypertensive pills. And the  influence of pharma companies is roughly equivalent in both specialties.
The real problem for lagging specialties is that they possess  numerous poorly studied, often recently approved drugs instead of a  small core arsenal of older drugs that are well-understood and so can  be dosed systematically. As the experience with leukemia shows, that’s  exactly the wrong way to cure disease. Successful specialties are  anchored by centralized, rigorous professional organizations that  served, over decades, as clearinghouses for study after study aimed at  calibrating therapy. Thus, cardiologists depended on the Framingham  Heart Study and the scientific committees of the American Heart  Association, pediatric oncologists have the Children’s Oncology Group,  and children’s lung specialists have the Cystic Fibrosis Foundation.  These specialties don’t pin all their hopes on new miracle cures;  instead, they do the grunt work of incremental clinical trials with the  pills they have. And as a result, they save many lives.
That doesn’t mean duplicating these successes is easy. Just as no automaker has successfully copied Toyota’s ingrained kaizen culture (which The New Yorker’s James Surowiecki likens to a hard-to-follow “regular, sustained diet”), the incremental doggedness of certain medical subspecialties resists imitation. But the lagging subfields should try.
Doctors in these fields first should take a long, hard look at their  priorities. Lagging fields are often the scene of paralyzing turf  battles between various institutions over clinical trials. By contrast,  the more successful specialties have overcome such pettiness and forged  nationwide partnerships to churn out study after study. The successful  specialties also encourage studies that choose incremental goals over  the big score.
Old Drugs, New Tricks Why big health advances rarely involve new medicines.